WANBURY
Small CapWanbury Limited
Pharma
Wanbury Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Investable fundamentals, management trust needs verification, price trend is neutral, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Bad · 10/100Rev -4% YoY · PAT +10% YoY · margin expansion · operating leverage
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹165 Cr | -4.1% | +1.9% |
| EBITDA | ₹30 Cr | +0.0% | +11.1% |
| Operating margin | 18.0% | +100 bps | +200 bps |
| PAT | ₹22 Cr | +10.0% | +37.5% |
| PAT margin | 13.3% | +170 bps | +345 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Issuer presentation review pending
Wanbury Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trend score and candlestick chart
55NeutralSMA20 +11.7% / mo
Technical chart
WANBURYweekly · 1Y-14.9%Technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 52. Wait for confirmation.
- SMA20 rising (~10.5% over last month) — short-term momentum positive.
- RSI(14) at 52 — rising, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 16% off 52W high · 65% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
UNDERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Fair-value margin of safety is positive at 51.7%.
- Quality contributes 20/20 to the score.
- Growth contributes 21/25 to the score.
Main drags
- Promoter pledge is 62.2%.
- Balance sheet is weaker at 0/15; verify the latest quarterly trend.
- Valuation is weaker at 12/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: -3 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Mixed Trust: Claim history is still being built. It ranks around the 19th percentile of the scored universe and 14th percentile within Pharma. Main check: promoter alignment is weak at 39/100.
Mixed Trust Lite: Promoter holding increased 3.4%. Key concern: Promoters have pledged 62.2% of holding.
Usable, but needs evidence. Treat guidance with a margin of safety.
overall median 67 · Pharma: 14th pctile, median 70 · Small: 23rd pctile, median 65
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Mixed Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding increased 3.4%.
- ▸10 years of positive FCF.
- ▸ROCE is 36.7%.
- ▸6/8 recent quarters had positive YoY revenue growth.
Trust risks
- ▸Promoters have pledged 62.2% of holding.
- ▸Debt/equity is 3.03.
- ▸3 recent quarters had PAT decline worse than 25% YoY.
- ▸ROCE trend is -3%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 20.50
- P/B
- 13.92
- EV/EBITDA
- 10.40
- Market Cap
- 882.00Cr
Profitability
- ROE
- 76.50%
- ROCE
- 36.70%
- ROA
- 10.39%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 10.00%
- EPS 5Y
- 31.00%
- Revenue 3Y
- 5.00%
- EPS 3Y
- 80.00%
Balance Sheet
- Debt/Equity
- 3.03
- Interest Coverage
- 2.38×
- Altman Z
- 3.85
- Book Value
- 18.10
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 10/5
- OCF
- 26.00 Cr
- EPS TTM
- 13.10
Shareholding
- Promoter Hold
- 43.01%
- Promoter Pledge
- 62.20%
- Momentum 52W
- 54%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.